Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Conditions
Interventions
OTL38
near infrared camera imaging system
+1 more
Locations
11
United States
The Mayo Clinic - Phoenix
Phoenix, Arizona, United States
University of Arizona
Tucson, Arizona, United States
City of Hope Medical Center
Duarte, California, United States
University of CA at Irvine Chao Cancer Center
Orange, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
Karmanos Cancer Institutes
Detroit, Michigan, United States
Start Date
January 26, 2018
Primary Completion Date
April 16, 2020
Completion Date
October 16, 2020
Last Updated
February 4, 2022
NCT03050268
NCT06257264
NCT06964009
NCT00539162
NCT06710548
NCT06915025
Lead Sponsor
On Target Laboratories, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions